Source: Citybizlist

Fusion Pharma: Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today reported... Read MoreThe post Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates appeared first on citybiz.

Read full article »
Fusion Pharma's Competitors | Fusion Pharma's News | Fusion Pharma's Financials
Stay up-to-date with the latest news on Fusion Pharma
Annual Revenue
$100K-5.0M
Employees
100-250
John Valliant's photo - CEO of Fusion Pharma

CEO

John Valliant

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Fusion Pharma